ERBB2 and breast cancer: In the phase III TULIP trial [47], which compared SYD985 with physician's choice chemotherapy in pretreated HER2‐positive breast cancer, the most frequent all‐grade AEs were fatigue (33.3%) and ocular toxicities (conjunctivitis, 38.2%; keratitis, 38.2%).